Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context
暂无分享,去创建一个
Adrian Towse | P. Danzon | A. Towse | Jorge Mestre-Ferrandiz | J. Mestre-Ferrandiz | Patricia M. Danzon
[1] Sean Flynn,et al. An Economic Justification for Open Access to Essential Medicine Patents in Developing Countries , 2009, The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics.
[2] T. Philipson,et al. Cost-effectiveness analysis and innovation. , 2008, Journal of health economics.
[3] Adrian Towse,et al. Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents , 2003, International Journal of Health Care Finance and Economics.
[4] A. Garber,et al. Economic foundations of cost-effectiveness analysis. , 1997, Journal of health economics.
[5] Insurance and Innovation in Health Care Markets , 2005 .
[6] Charles L. Ballard,et al. General Equilibrium Computations of the Marginal Welfare Costs of Taxes in the United States , 1985 .
[7] W. Jack,et al. Financing pharmaceutical innovation : how much should poor countries contribute? , 2005 .
[8] Andrew Briggs,et al. Value based pricing for NHS drugs: an opportunity not to be missed? , 2008, BMJ : British Medical Journal.
[9] Charles I. Jones,et al. Insurance and Incentives for Medical Innovation , 2006 .
[10] T. Philipson,et al. Integrated Insurance Design in the Presence of Multiple Medical Technologies , 2007, The American economic review.
[11] David L. Bradford,et al. Optimal Departures from Marginal Cost Pricing , 1970 .
[12] P. Danzon,et al. Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU , 1997 .
[13] E. Taylor,et al. Drug pricing and value in oncology. , 2010, The oncologist.
[14] Xavier Martinez-Giralt,et al. On international cost-sharing of pharmaceutical R&D , 2008, International Journal of Health Care Finance and Economics.
[15] Stefan Szymanski,et al. Parallel Trade, International Exhaustion and Intellectual Property Rights: A Welfare Analysis , 2005 .
[16] R. R. Braeutigam. Socially Optimal Pricing with Rivalry and Economies of Scale , 1984 .
[17] A. Garber,et al. Economic Foundations of Cost Effective Analysis , 1992 .
[18] David A. Malueg,et al. Parallel imports, demand dispersion, and international price discrimination* , 1994 .
[19] P. Danzon,et al. PHARMACEUTICAL PRICING IN EMERGING MARKETS: EFFECTS OF INCOME, COMPETITION, AND PROCUREMENT , 2011, Health economics.
[20] F. Ramsey. A Contribution to the Theory of Taxation , 1927 .
[21] T. Philipson,et al. Endogenous cost-effectiveness analysis and health care technology adoption. , 2013, Journal of health economics.
[22] T. Valletti,et al. Parallel Trade, Price Discrimination, Investment and Price Caps , 2005 .
[23] N. Sood,et al. Innovation and The Welfare Effects of Public Drug Insurance. , 2009, Journal of public economics.